Insmed's Phase 2b BiRCh study of brensocatib in CRSsNP did not meet primary or secondary efficacy endpoints.
The company acquired INS1148, a monoclonal antibody with potential in respiratory and immunological & inflammatory indications.
Brensocatib development in CRSsNP has been discontinued, and INS1148 is set for Phase 2 development programs.
The study results provided clear answers regarding the treatment benefit for patients with CRSsNP.
Phase 2b BiRCh Study Outcome
Brensocatib did not meet efficacy endpoints in CRSsNP, leading to program discontinuation.
Acquisition of INS1148
Insmed acquired INS1148, a monoclonal antibody for various respiratory and inflammatory diseases.
Future Development Plans
INS1148 will undergo Phase 2 development initially for interstitial lung disease and moderate-to-severe asthma.
- The discontinuation of the brensocatib program in CRSsNP indicates a strategic shift in Insmed's development focus towards potential therapies like INS1148.
- The acquisition of INS1148 adds a promising asset with a novel mechanism of action to Insmed's pipeline, aiming to address high unmet medical needs.
Insmed's decision to discontinue brensocatib in CRSsNP while acquiring INS1148 demonstrates the company's commitment to adapting its portfolio based on clinical outcomes and advancing innovative therapies to meet patient needs.